$开拓药业-B(09939)$ Agenda: The meeting presentations will be heard, viewed, captioned, and recorded
through an online teleconferencing platform. The committee will discuss the request for
Emergency Use Authorization 113, for sabizabulin oral capsule, a tubulin polymerization
inhibitor, submitted by Veru Inc., for the treatment of SARS-CoV-2 infection in moderate to
severe COVID-19 infections at high risk of acute respiratory distress syndrome. A focus of the
discussion will include the treatment effect size in the context of the high placebo mortality rate,
the limited size of the safety database, and identifying the proposed population
雪球：产业链观系